Vineet Puri, MD
Internal Medicine · Dover, DENPI 1548215981
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,970 of the $2,824 with a category attached, or 69.7%. 24 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 34.8% of the total. Reporting peaked in 2021 at $1,435 and has fallen 68.2% since, to $457 in 2024.
Across 103 payments — averaging $27.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$982
- AstraZeneca$339
- Novo Nordisk$305
- Lilly USA, LLC$215
- AbbVie$201
- GSK$150
- plus $631 from 18 others
What the payments were for
- Travel & lodging$85430%
- Food & beverage$1,97070%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 2 | $982 |
| AstraZeneca | 21 | $339 |
| Novo Nordisk | 19 | $305 |
| Lilly USA, LLC | 13 | $215 |
| AbbVie | 6 | $201 |
| GSK | 8 | $150 |
| Biohaven Pharmaceuticals, Inc. | 5 | $87 |
| Merck | 4 | $61 |
| Idorsia Pharmaceuticals US Inc | 3 | $60 |
| Pfizer | 3 | $58 |
| Dexcom, Inc. | 3 | $54 |
| Astellas Pharma US Inc | 3 | $52 |
| Abbott | 2 | $44 |
| Merz North America, Inc. | 1 | $36 |
| Tactile Systems Technology Inc | 1 | $29 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Novartis | 1 | $19 |
| G Medical Diagnostic Services, Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| Eisai Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,824 in reported general payments places this provider in the 85th percentile of 477 internal medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 15 | $58,825 |
| JardianceEmpagliflozin | 50 | $55,047 |
| OzempicSemaglutide | 51 | $53,743 |
| FarxigaDapagliflozin Propanediol | 32 | $40,241 |
| JanuviaSitagliptin Phosphate | 38 | $39,711 |
| TradjentaLinagliptin | 39 | $35,571 |
| EliquisApixaban | 30 | $25,672 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $16,742 |
| TrulicityDulaglutide | 15 | $13,286 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $12,239 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $11,834 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $4,362 |
| Atorvastatin Calcium | 337 | $3,421 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 98 | $3,086 |
| Omeprazole | 112 | $1,640 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $14 | $90,61989 claims |
| Novo NordiskOzempic | $305 | $53,74351 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $339 | $52,07649 claims |
| MerckJanuvia | $61 | $39,71138 claims |
| PfizerEliquis | $58 | $25,67230 claims |
| GSKTrelegy Ellipta | $150 | $16,74218 claims |
| Lilly USA, LLCTrulicity | $215 | $13,28615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 477 internal medicine providers in Delaware.
Other internal medicine in Dover
- Natwarlal RamaniDover$10K
- Adeniyi AjenifujaDover$9K
- Sandeep MannDover$6K
- Theodore Conrad TanDover$6K
- Abimbola OsunkoyaDover$5K
- Michael SweeneyDover$4K
- Seth IvinsNewark$384K
- Beshara HelouGeorgetown$143K
- Tabassum SalamNewark$62K
- Fabricio AlarconGeorgetown$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.